BCX logo

Bioceltix S.A. Stock Price

WSE:BCX Community·zł492.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

BCX Share Price Performance

zł99.90
24.20 (31.97%)
zł99.90
24.20 (31.97%)
Price zł99.90

BCX Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with very low risk.

2 Risks
0 Rewards

Bioceltix S.A. Key Details

zł0

Revenue

zł1.7m

Cost of Revenue

-zł1.7m

Gross Profit

zł12.3m

Other Expenses

-zł14.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-2.84
0%
0%
0%
View Full Analysis

About BCX

Founded
2018
Employees
36
CEO
Lukasz Bzdzion
WebsiteView website
bioceltix.com

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

Recent BCX News & Updates

Recent updates

No updates